Sacubitril-d_4 hemicalcium salt

Cat. No.:	HY-15407AS1
Molecular Formula:	$C_{24}H_{25}D_4NO_{50}{\cdot}_5Ca$
Molecular Weight:	435.56
Target:	Neprilysin; Isotope-Labeled Compounds
Pathway:	Metabolic Enzyme/Protease; Others
Storage:	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



BIOLOGICAL ACTIVITY

Description	Sacubitril-d_4 hemicalcium salt is the deuterium labeled Sacubitril hemicalcium salt (HY-15407A). Sacubitril hemicalcium salt is a potent NEP inhibitor with an IC_{50} of 5 nM[1][2][3][4].
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

[2]. Voors AA, et al. The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure. Expert Opin Investig Drugs. 2013 Aug;22(8):1041-7.

[3]. von Lueder TG, et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail. 2015 Jan;8(1):71-8.

[4]. Ksander GM, et al. Dicarboxylic acid dipeptide neutral endopeptidase inhibitors. J Med Chem. 1995 May 12;38(10):1689-700.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA